R&D

Technology

MABPRO, a.s. is focused on the development and commercialization of CA IX-targeted therapy and diagnostics.

Therapy

Therapy

The development of our pharmaceutical assets is currently at preclinical phase.

We believe that we will introduce our early-stage pharmaceuticals in the foreseeable future.

Diagnostics

Diagnostics

Even though hypoxia have significant prognostic and predictive value in the clinic, the best method for hypoxia assessment has not been established yet.

Results of all clinical studies strongly recommend to evaluate CA IX as an endogenous marker of tumor hypoxia and a biological factor of therapy resistance.

As response to these unmet needs of clinical practice we are developing the diagnostic products for CA IX detection. We will introduce them in the foreseeable future.

Contact

info@mabpro.sk

MABPRO, a.s.
Dúbravská cesta 2
(Westend Tower)
841 04 Bratislava
Slovak Republic

ID. No.: 36 831 930
VAT Reg. No.: SK2022456678
Registered in Commercial register of Bratislava I District Court
Section: Sa, file no.: 6337/B